Purchase Order 75N98026P00517

<p>The National Heart, Lung and Blood Institute (NHLBI) issued a purchase order to Psomagen Inc. on May 14, 2026, valued at $199,994.72 for Olink Explore HT proteomic analysis supporting a sickle cell disease study. Work is performed in Rockville, Maryland, with an ultimate completion date of November 21, 2026. The purchase order is a firm fixed-price, severable contract with no set-aside designation.</p>

This is a federal purchase order contract awarded by the National Heart, Lung and Blood Institute (NHLBI), a civilian agency under the National Institutes of Health (NIH), to Psomagen Inc., a genomics and molecular biology services company. The contract, valued at $15,344.80, is for Psomagen to provide OLINK EXPLORE HT (partial panel use) services to support next-generation sequencing-based proteomics analysis of plasma samples from hospitalized sepsis patients. The contract is not associated...

This is a $53,578 firm fixed-price purchase order awarded by the National Heart, Lung and Blood Institute (NHLBI) to Psomagen Inc., a subsidiary of Macrogen, Inc. The contract is for Psomagen to provide Multiplex Olink Proteomics Assays. This appears to be related to the NHLBI's Trans-Omics for Precision Medicine (TOPMed) initiative, as Psomagen holds a $500 million single-award Indefinite Delivery Vehicle (IDV) contract with NHLBI to support that program. The contract does not have a...

This $24,940 firm-fixed-price purchase order was awarded by the National Heart Lung and Blood Institute, a civilian agency, to Psomagen Inc., a for-profit manufacturer of genomic and molecular biology services. The contract is to provide the Olink Explore HT platform to support the Sickle Cell Branch's efforts to detect proteomic biomarkers in individuals with sickle cell disease. The award does not have a set-aside designation. Psomagen has previously received other federal contract awards...

This is a $24,000 firm fixed-price purchase order awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency under the National Institutes of Health (NIH), to Psomagen Inc., a for-profit genomics services company. The contract is for providing ongoing Olink proteomics analysis for Batch 2 of sickle cell disease patient samples as part of the NHLBI's Laboratory of Sickle Cell Genetics and Pathophysiology research program. The award is not set aside and has an ultimate...

This federal contract award is for $24,940.00 and was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Psomagen Inc., a for-profit manufacturer of genomics and molecular biology services. The contract is a Firm Fixed Price Purchase Order to provide the NHLBI's Sickle Cell Branch with the Olink assay, which will be used to study the profiling of plasma proteins among individuals with sickle cell disease. The contract has no set-aside designation and is...

This is a $24,940.00 firm fixed-price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Psomagen Inc., a for-profit manufacturer of goods. The contract is to provide products to the Sickle Cell Branch to support their effort to investigate plasma biomarkers for the diagnosis and treatment of sickle cell disease. Psomagen is a genomics and molecular biology services company based in Rockville, Maryland, and a subsidiary of Macrogen, Inc. The...

This is a $24,940 firm fixed-price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Psomagen Inc., a for-profit manufacturer and genomics/molecular biology services company, for Olink proteomic assays to support the Laboratory of Sickle Cell Genetics and Pathophysiology's research on the relationship between the TTR V122I genetic mutation and its protein variant. The award is not associated with a set-aside program and has an ultimate...

This is a $24,940 firm-fixed-price purchase order awarded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to Psomagen Inc., a genomics and molecular biology services company, to provide products for proteomic analysis on sickle cell plasma as part of ongoing sickle cell research efforts. The contract has an ultimate completion date of December 5, 2025. Psomagen Inc. is a subsidiary of Macrogen, Inc. and a for-profit manufacturer of goods that...

The National Institutes of Health National Heart Lung and Blood Institute awarded a $484,000 purchase order contract to Psomagen Inc., a subsidiary of Macrogen, Inc., to provide Whole Genome Sequencing on DNA. The contract has a period of performance starting on May 17, 2022 through May 16, 2023 and utilizes a firm fixed price pricing structure. The place of performance will be Potomac, Maryland. Psomagen Inc. will perform whole genome sequencing services on DNA samples for the National Heart...